2
|
Lichtenstein F, Iqbal A, de Lima Will SEA, Bosch RV, DeOcesano-Pereira C, Goldfeder MB, Chammas R, Trufen CEM, Morais KLP, de Souza JG, Natalino RJM, de Azevedo IJ, Nishiyama Junior MY, Oliveira U, Alves FIA, Araujo JM, Lobba ARM, Chudzinski-Tavassi AM. Modulation of stress and immune response by Amblyomin-X results in tumor cell death in a horse melanoma model. Sci Rep 2020; 10:6388. [PMID: 32286411 PMCID: PMC7156751 DOI: 10.1038/s41598-020-63275-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2019] [Accepted: 03/17/2020] [Indexed: 02/08/2023] Open
Abstract
We have investigated Amblyomin-X-treated horse melanomas to better understand its mode of action through transcriptome analysis and the in vivo model. Amblyomin-X is a Kunitz-type homologous protein that selectively leads to the death of tumor cells via ER stress and apoptosis, currently under investigation as a new drug candidate for cancer treatment. Melanomas are immunogenic tumors, and a better understanding of the immune responses is warranted. Equine melanomas are spontaneous and not so aggressive as human melanomas are, as this study shows that the in vivo treatment of encapsulated horse melanoma tumors led to a significant reduction in the tumor size or even the complete disappearance of the tumor mass through intratumoral injections of Amblyomin-X. Transcriptome analysis identified ER- and mitochondria-stress, modulation of the innate immune system, apoptosis, and possibly immunogenic cell death activation. Interactome analysis showed that Amblyomin-X potentially interacts with key elements found in transcriptomics. Taken together, Amblyomin-X modulated the tumor immune microenvironment in different ways, at least contributing to induce tumor cell death.
Collapse
Affiliation(s)
- Flavio Lichtenstein
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Asif Iqbal
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Sonia Elisabete Alves de Lima Will
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Rosemary Viola Bosch
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Carlos DeOcesano-Pereira
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Mauricio Barbugiani Goldfeder
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Roger Chammas
- ICESP, Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Carlos Eduardo Madureira Trufen
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Katia Luciano Pereira Morais
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Jean Gabriel de Souza
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Renato Jose Mendonça Natalino
- ICESP, Center for Translational Research in Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | | | | | - Ursula Oliveira
- Laboratório Especial de Toxinologia Aplicada - CeTICS, Butantan Institute, São Paulo, Brazil
| | - Francisco Ivanio Arruda Alves
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Jaqueline Mayara Araujo
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Aline Ramos Maia Lobba
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil.,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil
| | - Ana Marisa Chudzinski-Tavassi
- Laboratory of Molecular Biology, Butantan Institute, São Paulo, SP, Brazil. .,CENTD, Centre of Excellence in New Target Discovery, Butantan Institute, São Paulo, Brazil.
| |
Collapse
|